4 active not recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 4 |
Follow Marijuana Abuse: new trials by email Literature Review of Marijuana Abuse trials Research Report on Marijuana Abuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral and Topical Phytocannabinoids for Psoriasis Oral Cannabis Extract, Topical cannabis cream - Psoriasis Vulgaris | Phase 2 | Active not recruiting | Federal University of Latin American Integration | 37 | 2025-11-01 | 2026-09-24 |
| ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids Nabiximols, Temozolomide, Nabiximols-matched placebo - Glioblastoma, Brain Tumor | Phase 2 | Active not recruiting | University of Birmingham | 122 | 2023-02-03 | 2026-10-16 |
| Clinical Trial on Agitation in Alzheimer's Dementia IGC-AD1-Active, IGC-AD1-Placebo - Alzheimer Disease, Agitation,Psychomotor | Phase 2 | Active not recruiting | IGC Pharma, LLC | 164 | 2022-10-11 | 2026-09-30 |
| Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use Cannabidiol, Risperidone - Dual Diagnosis | Phase 2 | Active not recruiting | Lone Baandrup | 64 | 2021-06-01 | 2026-01-27 |
Aggression (1) · Alzheimer Disease (1) · Anxiety Disorders (1) · Brain Neoplasms (1) · Caregiver Burden (1) · Dementia (1) · Depression (1) · Glioblastoma (1) · Inflammation (1) · Psoriasis (1) · Psychomotor Agitation (1) · Psychotic Disorders (1) · Recurrence (1)
Chemically-Induced Disorders (4) · Mental Disorders (4) · Substance-Related Disorders (4) · Pathological Conditions, Signs and Symptoms (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Nervous System Diseases (2) · Pathologic Processes (2) · Aberrant Motor Behavior in Dementia (1) · Astrocytoma (1) · Behavior (1) · Behavioral Symptoms (1) · Central Nervous System Neoplasms (1) · Disease Attributes (1) · Dyskinesias (1)
nabiximols (2) · Cannabidiol (1) · Exercise (1) · Risperidone (1) · Temozolomide (1)
Federal University of Latin American Integration (1) · IGC Pharma, LLC (1) · Lone Baandrup (1) · University of Birmingham (1)
Brazil (1) · Canada (1) · Denmark (1) · Puerto Rico (1) · United Kingdom (1) · United States (1)
Fiona Collinson, MBBS, BSc, MRCP, FRCR, PhD (1) · Lone Baandrup, MD, PhD (1)
2018 (1)